Compumedics Limited (AU:CMP)
ASX:CMP
Want to see AU:CMP full AI Analyst Report?
Top Page
Compumedics Limited
(Sydney:CMP)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.24
▼(-29.41% Downside)
Action:Reiterated
Date:03/04/26
The score is weighed down primarily by weak profitability and cash flow metrics despite revenue growth, alongside bearish technical signals with the price below major moving averages. Valuation further pressures the score due to the extremely high P/E and no provided dividend yield.
Positive Factors
Gross margin strength
A sustained gross margin near 61% indicates durable product-level profitability and pricing power in diagnostic equipment and software. This margin buffer supports investment in R&D, aftermarket support and absorbs sales volatility, underpinning long-term margin sustainability and product competitiveness.
Negative Factors
Weak profitability
Persistent negative net margin and razor-thin EBIT margin indicate the business struggles to translate sales into sustainable profits. Over several months this limits retained earnings for reinvestment, constrains returns to shareholders and raises sensitivity to cost inflation or lower volumes.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin strength
A sustained gross margin near 61% indicates durable product-level profitability and pricing power in diagnostic equipment and software. This margin buffer supports investment in R&D, aftermarket support and absorbs sales volatility, underpinning long-term margin sustainability and product competitiveness.
Read all positive factors
Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$48.94M
Dividend YieldN/A
Average Volume (3M)87.45K
Price to Earnings (P/E)449.0
Beta (1Y)0.69
Revenue Growth24.45%
EPS GrowthN/A
CountryAU
Employees155
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)<0.01
Shares Outstanding199,761,750
10 Day Avg. Volume153,799
30 Day Avg. Volume87,448
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.12
Price to Sales (P/S)0.91
P/FCF Ratio99.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Compumedics Limited Business Overview & Revenue Model
Company Description
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific regio...
How the Company Makes Money
Compumedics makes money mainly by selling medical diagnostic equipment and the software platforms that operate and analyze data from that equipment. Key revenue streams typically include: (1) capital equipment sales—one-time sales of sleep and neu...
Compumedics Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.49M | 51.04M | 49.72M | 42.41M | 37.76M | 35.74M |
| Gross Profit | 34.10M | 30.99M | 26.07M | 21.59M | 19.32M | 19.16M |
| EBITDA | 4.29M | 1.94M | 2.79M | -5.05M | 3.31M | 2.56M |
| Net Income | 109.00K | -1.27M | -338.00K | -6.12M | 1.36M | 998.00K |
Balance Sheet | ||||||
| Total Assets | 54.18M | 54.39M | 40.36M | 41.18M | 41.71M | 38.55M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 2.69M | 1.89M | 3.80M | 7.29M | 6.77M |
| Total Debt | 14.03M | 13.88M | 8.58M | 9.47M | 6.55M | 5.82M |
| Total Liabilities | 30.81M | 32.57M | 22.15M | 22.89M | 18.12M | 16.39M |
| Stockholders Equity | 23.37M | 21.82M | 18.21M | 18.29M | 23.59M | 22.16M |
Cash Flow | ||||||
| Free Cash Flow | 4.56M | 467.00K | -986.00K | -4.36M | 302.00K | -230.00K |
| Operating Cash Flow | 4.61M | 681.00K | 2.00M | 49.00K | 3.29M | 1.32M |
| Investing Cash Flow | -5.58M | -7.37M | -2.99M | -4.41M | -2.98M | -1.55M |
| Financing Cash Flow | -1.10M | 6.10M | -1.49M | -1.00M | 1.61M | -179.00K |
Compumedics Limited Technical Analysis
Negative
0.34
Price Trends
0.28
Negative
0.31
Negative
0.32
Negative
Market Momentum
-0.01
Positive
19.71
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.28, and above the 200-day MA of 0.32, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 19.71 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMP.
Compumedics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$127.07M | -49.15 | -5.31% | ― | 18.21% | 65.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$35.84M | -4.43 | -98.14% | ― | 14.88% | 35.94% | |
45 Neutral | AU$14.04M | -0.50 | -165.13% | ― | 23.30% | -14.29% | |
44 Neutral | AU$74.38M | -3.77 | -54.48% | ― | 17.24% | -20.00% | |
44 Neutral | AU$148.73M | -14.16 | -70.29% | ― | ― | -62.15% | |
42 Neutral | AU$48.94M | 449.01 | 0.48% | ― | 24.45% | ― |
* Healthcare Sector Average
AU:CMP
Compumedics Limited
0.25
-0.03
-10.91%
AU:IPD
Impedimed Limited
0.01
-0.02
-54.84%
AU:SOM
Somnomed Limited
0.58
-0.05
-7.94%
AU:CYC
Cyclopharm Limited
0.59
-0.45
-43.27%
AU:EMV
EMvision Medical Devices Ltd.
1.60
-0.24
-13.04%
AU:CBL
Control Bionics Ltd.
0.09
0.06
200.00%
Compumedics Limited Corporate Events
Compumedics Taps Veteran Medtech Leader to Drive U.S. Growth
Jun 9, 2026
Compumedics Limited, a global provider of sleep diagnostics, neurodiagnostic systems and ultrasonic blood flow monitoring technology, has expanded from its Australian base through its Neuroscan and DWL subsidiaries into key international markets. ...
Compumedics Flags Record FY26 Results Despite Timing Delays, Positions for Stronger FY27
Apr 21, 2026
Compumedics reported sustained order momentum across its sleep, neurology and MEG platforms, underpinned by growing SaaS and annuity revenues that improve visibility and the quality of future income. The company expects record revenue of about $62...
Compumedics Targets FY26 Growth as It Builds on Global Neurodiagnostics Leadership
Mar 24, 2026
Compumedics Limited, an Australian-headquartered medical technology group, develops and supplies diagnostic systems for sleep and neurological disorders, as well as ultrasonic brain blood flow monitoring equipment. With more than 25,000 systems in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.